跳至主要内容
临床试验/jRCT2080225077
jRCT2080225077已完成1 期

A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Chugai Pharmaceutical Co., Ltd.1 个研究点目标入组 12 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Open-label, dose escalation
主要目的
Treatment Purpose

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • CD20 positive B cell NHL that is recurrent or refractory to standard therapy or for which no standard therapy exists.
  • Pathologically confirmed B cell NHL.
  • ECOG PS of 0 or
  • Life expectancy =>12 weeks from the date of enrollment.
  • Major organ function meets all criteria.

排除标准

  • Pregnant or lactating woman.
  • Current or previous autoimmune disease.
  • Positive test result for human immunodeficiency virus antibody, hepatitis B surface antigen, HBs antibody, hepatitis B core antibody, or hepatitis C virus antibody.
  • Current or previous clinically significant liver disease.
  • Current central nervous system lymphoma, metastases to the CNS, or meningeal metastases.
  • History of previous therapy with allogenic hematopoietic stem cell transplantation or solid organ transplantation.
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or fusion proteins.

结局指标

主要结局

-

safety pharmacokinetics other other(DLT) NCI CTCAE

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验